News Release More August 2, 2022 Notice Regarding Decision on Termination and Dissolution of Business in Consolidated Subsidiaries, ActivX Biosciences, Inc. August 2, 2022 First Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2023 (Aug 2, 2022) - Supplementary Information August 2, 2022 Summary of Consolidated Financial Results(For the first quarter ended June 30, 2022) [Japanese Standard] June 17, 2022 KYORIN Signs Joint Development and License Agreement for Genetically modified Adipocyte, Treatment Agent for Fabry Disease May 17, 2022 Notice of Resumption of Operation at Nishinihon Delivery Center May 11, 2022 Notice of Reduction of Capital Reserve May 11, 2022 Absorption Type Merger (Simplified Merger and Short-Form Merger) of Wholly Owned Subsidiary KYORIN Pharmaceutical Co., Ltd., Change of Trade Name and Partial Amendment to Articles of Incorporation May 11, 2022 Consolidated Financial Results for the Fiscal Year Ended March 31, 2022 (May 11, 2022) - Supplementary Information Latest IR Events More First Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2023 Summary of consolidated Financial Results [ PDF 149.3 KB ] Supplementary Information [ PDF 533.2 KB ] Top Message Products Under Development IR Events Financial Information Financial Highlights Financial Indicators Business Segment/Main Products Cash Flows Capital Investment/Depreciation/R&D Costs Download Financial Data IR Library Summary of ConsolidatedFinancial Results/Presentation Document Annual Report Stock Information Shareholders Meeting Shareholder Return/Dividends General Information Stock Quote Business Risks Disclaimer FAQ Disclosure Policy